Bazedoxifene/conjugated estrogens
Bazedoxifene/conjugated estrogens, sold under the brand name Duavee in the US and Duavive in the EU, is a fixed-dose combination medication for the treatment of menopause symptoms and postmenopausal osteoporosis.[2] It contains the selective estrogen receptor modulator bazedoxifene and conjugated estrogens. It is taken by mouth.
| Combination of | |
|---|---|
| Bazedoxifene | Selective estrogen receptor modulator |
| Conjugated estrogens | Estrogen |
| Clinical data | |
| Trade names | Duavee, Duavive |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a614004 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider |
|
| KEGG | |
The combination was approved for medical use in the United States in October 2013,[3] and in the European Union in December 2014.[4]
Recall
In June 2020, Pfizer recalled recalled two batches of Duavive, its oestrogen replacement product, as a result of concerns raised about faulty packaging.[5]
References
- "Bazedoxifene / conjugated estrogens (Duavee) Use During Pregnancy". Drugs.com. 16 February 2019. Retrieved 23 June 2020.
- "Duavee. Generic Name: conjugated estrogens and bazedoxifene tablets". rxlist.com.
- "Drug Approval Package: Duavee (conjugated estrogens and bazedoxifene) NDA #022247". U.S. Food and Drug Administration (FDA). 7 October 2013. Retrieved 23 June 2020.
- "Duavive EPAR". European Medicines Agency (EMA). Retrieved 2020-06-10.
- "Pfizer recalls 2 batches of Duavive". Zenopa.
External links
- "Bazedoxifene mixture with conjugated estrogens". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.